FGF21 and metabolic dysfunction-associated steatohepatitis: Notably, muscle-targeted AAV1-FGF21 gene therapy reverses metabolic dysfunction-associated steatohepatitis (MASH) progression in mice (14), but its role in muscle remains incompletely understood.